Research category

DIRECTOR

Flynn LL, Mitrpant C, Pitout IL, Fletcher S, and Wilton SD, Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Mol Ther Nucleic Acids, 2018. (in press).

Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, and Stick SM, The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 2018. 5(1): p. 3.

NHMRC Optimization of splice switching therapies to treat Duchenne muscular dystrophy”. Bellgard MI, Wilton SD, Fletcher S. $439,000

NHMRC The L-type calcium as a reporter of successful morpholino oligomer therapy in treatment of Duchenne muscular dystrophy cardiomyopathy”. Hool L, Fletcher S, Wilton SD. $575,558

Targeted alternative splicing: a common therapeutic platform to treat inherited diseases Wilton, Fletcher, Zheng, Mastaglia 2018-2020 $798,165. NHMRC Application 1144791

Targeted alternative splicing: a common therapeutic platform to treat inherited diseases Wilton, Fletcher, Zheng, Mastaglia 2018-2020 $798,165. NHMRC Application 1144791

NHMRC European Union RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research $989,884